News & sentiment

IMRX (IMRX) — News & AI sentiment

IMRX news roundup. 3 stories in the past week, 5 over 30 days. Average 30-day sentiment is 67.2/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

7d stories

avg sentiment 70.3/100

30d stories

avg sentiment 67.2/100

Insider net (90d)

0 buys · 0 sells

Congress (90d)

0 buys · 0 sells

Latest stories on IMRX

Immuneering Advances Atebimetinib With Positive Phase 2a Results

TipRanks67 · bullishproduct/pr

6d ago

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Seeking Alpha67 · bullishproduct/pr

7d ago

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO | IMRX Stock News

StockTitan77 · bullishproduct/pr

7d ago

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | IMRX Stock News

StockTitan67 · bullishproduct/pr

May 21

Immuneering GAAP EPS of -$0.21 beats by $0.04

Seeking Alpha58 · neutralearnings

May 15

Open IMRX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →